How much profit has Biontech made this year?
Biontech has made -761.53 M EUR this year.
Biontech Net Income 2024
Biontech Net Income
-761.53 M EUR
Ticker
BNTX
ISIN
US09075V1026
WKN
A2PSR2
In 2024, Biontech's profit amounted to -761.53 M EUR, a -181.86% increase from the 930.3 M EUR profit recorded in the previous year.
The Biontech Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2029e | 0.51 |
| 2028e | 0.1 |
| 2027e | -0.57 |
| 2026e | -0.65 |
| 2025e | -0.8 |
| 2024e | -0.76 |
| 2023 | 0.93 |
| 2022 | 9.43 |
| 2021 | 10.29 |
| 2020 | 0.02 |
| 2019 | -0.18 |
| 2018 | -0.05 |
| 2017 | -0.09 |
Biontech Revenue, EBIT, Net Income US09075V1026 · A2PSR2
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Biontech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biontech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biontech’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Biontech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Biontech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Biontech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biontech’s growth potential.
Biontech Revenue, EBIT and net profit per share
| Date | Biontech Revenue | Biontech EBIT | Biontech Net Income |
|---|---|---|---|
| 2029e | 4.81 B undefined | 520.07 M undefined | 514.06 M undefined |
| 2028e | 3.9 B undefined | -229.94 M undefined | 101.34 M undefined |
| 2027e | 3.06 B undefined | -1.15 B undefined | -572.48 M undefined |
| 2026e | 2.6 B undefined | -1.32 B undefined | -651.03 M undefined |
| 2025e | 2.63 B undefined | -1.21 B undefined | -803.43 M undefined |
| 2024e | 2.66 B undefined | -1.29 B undefined | -761.53 M undefined |
| 2023 | 3.82 B undefined | 908 M undefined | 930.3 M undefined |
| 2022 | 17.31 B undefined | 12.3 B undefined | 9.43 B undefined |
| 2021 | 18.98 B undefined | 14.78 B undefined | 10.29 B undefined |
| 2020 | 482 M undefined | -82 M undefined | 15 M undefined |
| 2019 | 109 M undefined | -182 M undefined | -179 M undefined |
| 2018 | 128 M undefined | -54 M undefined | -48 M undefined |
| 2017 | 62 M undefined | -61 M undefined | -86 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2017 | 62 M EUR | -61 M EUR | -86 M EUR |
| 2018 | 128 M EUR | -54 M EUR | -48 M EUR |
| 2019 | 109 M EUR | -182 M EUR | -179 M EUR |
| 2020 | 482 M EUR | -82 M EUR | 15 M EUR |
| 2021 | 18.98 B EUR | 14.78 B EUR | 10.29 B EUR |
| 2022 | 17.31 B EUR | 12.3 B EUR | 9.43 B EUR |
| 2023 | 3.82 B EUR | 908 M EUR | 930.3 M EUR |
| 2024e | 2.66 B EUR | -1.29 B EUR | -761.53 M EUR |
| 2025e | 2.63 B EUR | -1.21 B EUR | -803.43 M EUR |
| 2026e | 2.6 B EUR | -1.32 B EUR | -651.03 M EUR |
| 2027e | 3.06 B EUR | -1.15 B EUR | -572.48 M EUR |
| 2028e | 3.9 B EUR | -229.94 M EUR | 101.34 M EUR |
| 2029e | 4.81 B EUR | 520.07 M EUR | 514.06 M EUR |
Biontech stock margins US09075V1026 · A2PSR2
The Biontech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biontech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biontech.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Biontech's sales revenue. A higher gross margin percentage indicates that the Biontech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Biontech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Biontech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biontech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biontech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biontech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Biontech Margin History
| Biontech Gross margin | Biontech Profit margin | Biontech EBIT margin | Biontech Profit margin |
|---|---|---|---|
| 2029e | 84.29 % | 10.82 % | 10.69 % |
| 2028e | 84.29 % | -5.89 % | 2.6 % |
| 2027e | 84.29 % | -37.47 % | -18.73 % |
| 2026e | 84.29 % | -50.75 % | -25.04 % |
| 2025e | 84.29 % | -46.09 % | -30.57 % |
| 2024e | 84.29 % | -48.35 % | -28.64 % |
| 2023 | 84.29 % | 23.78 % | 24.36 % |
| 2022 | 82.7 % | 71.05 % | 54.5 % |
| 2021 | 84.66 % | 77.89 % | 54.24 % |
| 2020 | 87.76 % | -17.01 % | 3.11 % |
| 2019 | 83.49 % | -166.97 % | -164.22 % |
| 2018 | 89.06 % | -42.19 % | -37.5 % |
| 2017 | 83.87 % | -98.39 % | -138.71 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2017 | 83.87 % | -98.39 % | -138.71 % |
| 2018 | 89.06 % | -42.19 % | -37.5 % |
| 2019 | 83.49 % | -166.97 % | -164.22 % |
| 2020 | 87.76 % | -17.01 % | 3.11 % |
| 2021 | 84.66 % | 77.89 % | 54.24 % |
| 2022 | 82.7 % | 71.05 % | 54.5 % |
| 2023 | 84.29 % | 23.78 % | 24.36 % |
| 2024e | 84.29 % | -48.35 % | -28.64 % |
| 2025e | 84.29 % | -46.09 % | -30.57 % |
| 2026e | 84.29 % | -50.75 % | -25.04 % |
| 2027e | 84.29 % | -37.47 % | -18.73 % |
| 2028e | 84.29 % | -5.89 % | 2.6 % |
| 2029e | 84.29 % | 10.82 % | 10.69 % |
Biontech Aktienanalyse
What does Biontech do?
BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Biontech's Profit Margins
The profit margins of Biontech represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Biontech's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Biontech's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Biontech's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Biontech’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Biontech stock
How has the profit developed compared to last year?
The profit has increased by -181.86% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Biontech publish its earnings?
Biontech publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Biontech?
The profits of Biontech are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Biontech?
You can learn more about the earnings of Biontech by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Biontech pay?
Over the past 12 months, Biontech paid a dividend of 2.13 EUR . This corresponds to a dividend yield of about 1.98 %. For the coming 12 months, Biontech is expected to pay a dividend of -0.19 EUR.
What is the dividend yield of Biontech?
The current dividend yield of Biontech is 1.98 %.
When does Biontech pay dividends?
Biontech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biontech?
Biontech paid dividends every year for the past 2 years.
What is the dividend of Biontech?
For the upcoming 12 months, dividends amounting to -0.19 EUR are expected. This corresponds to a dividend yield of -0.18 %.
In which sector is Biontech located?
Biontech is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biontech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biontech from 6/17/2022 amounting to 2.132 EUR, you needed to have the stock in your portfolio before the ex-date on 6/2/2022.
When did Biontech pay the last dividend?
The last dividend was paid out on 6/17/2022.
What was the dividend of Biontech in the year 2023?
In the year 2023, Biontech distributed 2.132 EUR as dividends.
In which currency does Biontech pay out the dividend?
The dividends of Biontech are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biontech stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von Biontech
Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
